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Abstract: Acute heart failure (AHF) emerges as a major and
growing epidemiological concern with high morbidity and mortality
rates. Current therapies in patients with acute heart failure rely on
different strategies. Patients with hypotension, hypoperfusion, or
shock require inotropic support, whereas diuretics and vasodilators
are recommended in patients with systemic or pulmonary conges-
tion. Traditionally inotropic agents, referred to as Ca2+ mobilizers
load the cardiomyocyte with Ca2+ and thereby increase oxygen con-
sumption and risk for arrhythmias. These limitations of traditional
inotropes may be avoided by sarcomere targeted agents. Direct acti-
vation of the cardiac sarcomere may be achieved by either sensitiz-
ing the cardiac myoﬁlaments to Ca2+ or activating directly the
cardiac myosin. In this review, we focus on sarcomere targeted
inotropic agents, emphasizing their mechanisms of action and over-
view the most relevant clinical considerations.
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INTRODUCTION
Heart failure (HF) is a complex pathophysiological
syndrome involving acute and chronic phenomena. Acute
heart failure (AHF) relates to the rapid decline in cardiac
pump function requiring urgent medical care. More than 1
million hospitalizations occur annually in the United States
because of AHF, and hence it emerges as a major and
growing public health burden over the past 2 decades.1 In
addition to its high incidence, AHF is also associated with
high mortality rates; the estimated risk of death was reported
around 3%–4% in the hospital and approximately 10% after
discharge within 60–90 days.2
AHF may arise as a de novo entity in a previously
asymptomatic patient or as an acute exacerbation of
previously diagnosed chronic HF. According to the current
ESC guidelines, AHF is referred in this review as
a complex clinical syndrome including the following
conditions: worsening or decompensated chronic HF,
pulmonary edema, hypertensive acute HF, cardiogenic
shock, HF related to acute coronary syndromes, and
isolated right-sided HF.3
Current pharmacological therapies should respect the
distinct clinical and pathophysiological entities of the AHF
syndromes. Accordingly, in those patients with hypotension,
hypoperfusion, or shock, intravenous inotropic support
should be considered to maintain the peripheral perfusion
by increasing the cardiac output (CO) and the blood pressure,
whereas intravenous diuretics and vasodilators are recom-
mended in patients with pulmonary and/or systemic venous
congestion, as well as with signs of elevated ﬁlling pressures
and vascular volume redistribution.4
Unfortunately, not a single conventional treatment
strategy proved convincingly effective in reducing HF
symptoms and improving short- and long-term mortality
rates.4 Moreover, several HF drugs were shown to increase
mortality and morbidity over placebo.5 For this reason, newly
developed cardiovascular agents were designed to have dif-
ferent mechanisms of action from those of traditional drugs.
In this review, we will focus on recently developed cardio-
vascular medications and will put speciﬁc emphasis on poten-
tial drug interactions with the cardiac sarcomere.
PATHOPHYSIOLOGY OF AHF SYNDROME
Brieﬂy, the pathophysiology of AHF relies on a com-
plex interaction between the weakened cardiac performance
and increased systemic vascular resistance (SVR). A novel
paradigm suggests that episodes of AHF can be classiﬁed as
either an acute vascular or cardiac failure.6 Decline in the
cardiac performance by diverse pathological processes (eg,
myocardial ischemia and arrhythmia) results in a forward
and backward failure, manifesting as low peripheral perfusion
with renal impairment and ﬂuid accumulation with severe
pulmonary congestion. The vascular pathway is related to
the increased SVR and arterial stiffness leading to elevations
in the left ventricular end-diastolic pressure. Hence, increased
LV ﬁlling pressure contributes to pulmonary congestion with
concomitant signs of AHF.7 Although one or another pathway
dominates in certain clinical cases, the combination of the
above pathologic pathways results in the initiation of AHF
by promoting a vicious circle.
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ROLE OF INOTROPIC AGENTS IN THE THERAPY
OF AHF SYNDROMES
The core of the problem in acute and chronic HF relates
to impaired cardiac performance, and hence cardiovascular
drugs supporting the pump function (ie, positive inotropic
agents) of the failing human heart appeared for a long time as
an optimal therapeutic approach. Inotropic agents can be
classiﬁed by their mechanisms of actions, and the majority of
cardiotonic drugs currently in clinical use can be referred to as
calcium (Ca2+) mobilizers acting by increasing the amplitude
of the intracellular Ca2+ transient. Over the years, an alternative
approach received increasingly more and more attention to
support the failing human heart by targeting the cardiac sar-
comere. This strategy is attractive because it promises to evoke
positive inotropy without changes in the Ca2+ homeostasis.8
Mechanism of Action and Clinical
Implications for Ca2+ Mobilizers
Ca2+ mobilizer inotropic agents load the cardiomyo-
cytes with Ca2+ to improve cardiac contractility. Hence, this
inotropic intervention can be complicated by deleterious ef-
fects limiting its applicability in long-term therapies for pa-
tients with AHF syndrome.9 This is because cardiomyocyte
Ca2+ loading is associated with enhanced myocardial oxygen
(O2) consumption, increased heart rate (HR), and greater risk
of arrhythmias contributing to the higher morbidity and mor-
tality rates.10
Ca2+ mobilizer agents interfere with various mechanisms
of the cardiac excitation–contraction coupling.11 Cardiac glyco-
sides (eg, digitalis alkaloids) were the ﬁrst inotropic drugs
administered for the therapy of HF. Digoxin was shown to
increase Ca2+ inﬂux into the cytoplasm by interfering the sar-
colemmal sodium–calcium exchange process because of its
inhibitory action on the sodium–potassium ATPase (Na+-K+
ATPase).12 Although digoxin reduced the rate of hospitaliza-
tion because of worsening of HF, long-term mortality rates
seemed to be unchanged, and hence clinical data do not con-
ﬁrm a clear beneﬁt on mortality for digoxin treatment.13,14
The b-adrenergic agonists and inhibitors of the phos-
phodiesterase III (PDE III) isoenzyme may also evoke a pos-
itive inotropic effect by interfering with cyclic adenosine
monophosphate (cAMP)–dependent phosphorylation pro-
cesses. Dobutamine, a selective b-adrenergic agonist, increase
the intracellular Ca2+ level through activating this signaling
pathway leading to protein kinase A activation. Continuous
intravenous dobutamine administration was shown to be asso-
ciated with increased 6-month mortality rate according to the
FIRST trial.15 Nevertheless, low-dose intravenous dopamine
infusion and dobutamine administration result in renal vaso-
dilatation due to b2-adrenergic receptor activation.16 Dobut-
amine is also suspected to decrease renal sympathetic activity
contributing to a beneﬁcial effect on the renal function.17
Because worsening of renal function is associated with a poor
prognosis, renal vasodilatation might be favorable in patients
hospitalized for AHF syndrome.18 PDE III inhibitors (eg,
milrinone and enoximone) enhance contractility in cardiac
myocytes and relaxation in the vascular smooth muscle cells
by reducing the rate of cAMP breakdown. Intravenous
milrinone administration had no beneﬁcial effect on the
intermediate-term clinical outcome when compared with that
of placebo in acute exacerbation of chronic HF.19 Moreover,
oral milrinone therapy resulted in increase of morbidity and
mortality rates in those of patients with decompensated HF.5
Simultaneous modulation of the sarcoplasmic reticulum
ATPase 2a (SERCA-2a) and Na+-K+ ATPase activity may
also provide a cardiotonic effect. Accordingly, istaroxime
was proposed for the treatment of AHF through Na+-K+
ATP-ase inhibition similarly to that of cardiac glycosides
and simultaneous enhancement in sarcoplasmic reticulum
(SR) Ca2+ uptake by increasing the activity of the SER-
CA2a.20 These changes in the Ca2+ handling would then pro-
mote myocardial contraction and relaxation and evoking
thereby a positive ino-lusitropic effect.20 Some clinical data
conﬁrmed the beneﬁcial cardiovascular effects of istaroxime
because patients with AHF were reported with increased ven-
tricular ﬁlling and systolic blood pressure as well as with
decreased wedge pressure values after istaroxime treatment.21
Nevertheless, cardiovascular drugs promoting Ca2+ cycling
through the SR [eg, istaroxime and nitroxyl (HNO) donors]
might be also referred to as SR Ca2+ cycling enhancers to
emphasize their mechanism of action involving simultaneous
increase in the rate of Ca2+ release and re-uptake in contrast to
the traditionally inotropes.
Activators of the cardiac ryanodin receptor 2 (eg, HNO
donor CXL-1020) promote Ca2+ release from the SR and
thereby it also exerts an inotropic effect.22 Further investiga-
tions are required to see how this effect can be exploited in
the clinical arena (Table 1).
SARCOMERE TARGETED AGENTS: A NOVEL
THERAPEUTIC APPROACH FOR AHF SYNDROME
Several different terms and concepts have been associ-
ated with cardiac sarcomere targeted agents, that is, Ca2+
sensitization of contractile ﬁlaments, direct cardiac myosin
activation, and cardiovascular drugs with added myoﬁlamen-
tal effects (eg, SR-33805 and HNO donors).
Theoretically, clinical use of sarcomere targeted drugs
would avoid the disadvantages of Ca2+ mobilizers in the ther-
apy of AHF syndrome.11 This is because pharmacological
modiﬁcation of the cardiac sarcomere is not expected to inter-
fere with the intracellular Ca2+ homeostasis at all or not to the
same degree, hence their clinical application should not be
associated either with increased risk of arrhythmias or cell
injury.23 Furthermore, sarcomere activating inotropes exert
their cardiotonic effects presumably without considerable
changes in myocardial O2 consumption, and thereby they
can improve the efﬁciency of chemomechanical energy trans-
duction of the contractile protein machinery.24 Finally, car-
diac sarcomere targeted agents can be effective in the
diseased myocardium, where cardiac dysfunction is accom-
panied by diverse pathophysiological conditions (eg, acidosis
and ischemia-reperfusion injury).11
Historically, the concept of direct sarcomere targeting
emerged for over 2 decades, when AR-L 115BS was reported
as a potent inotropic agent involving direct activation of the
myoﬁlaments through increased afﬁnity of the thin ﬁlaments
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for Ca2+.25 Unfortunately, the ﬁrst molecule was shown to
have deleterious activities because AR-L 115BS also acts
through A1 adenosine receptor antagonism and inhibition of
Gi function resulting in a cAMP and consequently Ca2+ accu-
mulation.26 Nevertheless, newly designed drugs with directly
sarcomere targeted effects seemed soon due to the emergence
of the new concept for improving cardiac performance while
avoiding deleterious activities (Box 1).
POTENTIAL USEFULNESS OF CA2+ SENSITIZER
DRUGS IN AHF SYNDROME
Ca2+ sensitization refers to increased contractile force
production at a given Ca2+ concentration.8 In fact, force aug-
mentation can be achieved through different molecular mecha-
nisms leading to various modiﬁcations in the [Ca2+]–contractile
force relationship (Fig. 1). First of all, different kinases and
phosphatases have the potential to modulate the phosphoryla-
tion status of myoﬁlamental proteins, and hence they offer
pharmacological targets for the modulation of the myoﬁlamen-
tal response to Ca2+.27,28 Moreover, certain drugs targeting the
interaction between cardiac troponin C (cTnC) and troponin I
(cTnI) (eg, levosimendan) were also demonstrated to sensitize
the myoﬁlaments to Ca2+, and this effect can thus evoke a left-
ward shift in the [Ca2+]–contractile force relationship without
increases in force production at maximal or minimal Ca2+ con-
centrations.27,29 Downstream from these regulatory contractile
proteins, the actin–myosin interface can serve also as a potential
target for Ca2+ sensitizing drugs. Using this mechanism, EMD-
57033 was shown to evoke prominent Ca2+ sensitization;
nevertheless, this effect was accompanied by force augmenta-
tion not only at saturating Ca2+ levels but even at diastolic Ca2+
concentrations thereby compromising diastolic relaxation.27,30,31
Finally, Ca2+ sensitization may reﬂect simply an elevation of
the maximal Ca2+-activated force production without changes
in the midpoint of [Ca2+]–contractile force relationship.8,27
Levosimendan, the Inodilator Ca2+ Sensitizer
Levosimendan [the (2) enantiomer of 4-(1,4,5,6-
tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenylhydrazonopro-
panedinitrile] is currently the only Ca2+-sensitizer drug
suggested for the treatment of the acute HF syndrome by
ESC guidelines. The mechanisms of action for levosimendan
involves 3 major processes: Ca2+ sensitization through a selec-
tive binding to the Ca2+-saturated cTnC; opening of ATP-
sensitive potassium (KATP) channels in the vascular smooth
muscle cells and those of in the mitochondria (Fig. 2).32
Ca2+ Sensitizing Effect of Levosimendan
The troponin complex formed by 3 smaller proteins
(cTnC, cTnT, and cTnI) is the sarcomeric Ca2+ sensitive reg-
ulator of skeletal and cardiac muscle contraction. During sys-
tole, binding of Ca2+ to the regulatory sites of cTnC enhances
its interaction with cTnI and results in a dissociation of the
TABLE 1. Inotropic Mechanisms and Drugs
Inotropic Agents
Calcium mobilizers
Na+-K+ ATPase inhibitors digoxin
PDE-inhibitors enoximone, milrinone, pimobendan
b-adrenegic agonists adrenaline, dopamine, dobutamine
Sarcoplasmic reticulum Ca2+ cycling
enhancers
Na+-K+ ATPase inhibitor +
SERCA activator
istaroxime
Ryanodine receptor 2 and SERCA
activator
CXL-1020
Sarcomere targeted agents
Ca2+ sensitizers levosimendan, pimobendan
Myosin activator omecamtive mecarbil
Drugs with added myoﬁlamental
effects
SR-33805, CXL-1020
FIGURE 1. Ca2+ sensitization refers to increased contractile
force production at a given Ca2+ concentration. Levosimendan
(B) evokes a leftward shift in the [Ca2+]–contractile force
relationship without increase in the force production at max-
imal and minimal Ca2+ concentrations (control) (A). Ca2+
sensitization can involve force augmentations at diastolic Ca2+
concentrations and in the maximal force values (C). Theoret-
ically, Ca2+ sensitizers might evoke increases only in the
maximal force production (D).
Implications for Sarcomere Targeted Agents
! The application of inotropes can be complicated by
deleterious side effects due to an increased Ca2+ load
for cardiomyocytes
! Sarcomeric proteins are increasingly considered as
potential new pharmacological targets to achieve
positive inotropy without Ca2+ loading of the cardi-
omyocytes
! Modulation of different contractile proteins convey
distinct mechanical responses
! Sarcomere targeted drugs may have additional car-
diovascular effects
! Sarcomere activation may result in a favorable clini-
cal outcome in selected patient populations
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inhibitory domain of cTnI from the actin ﬁlaments.33
Moreover, Ca2+-activated structural changes of cTnC may
also evoke conformational alterations of the tropomyosin
binding cTnT, promoting the translocation of the troponin–
tropomyosin complex away of the actin ﬁlaments to uncover
the myosin binding sites on actin.34 All of these changes will
contribute to the transition of the actin–troponin–tropomyosin
complex from the blocked towards its force-generating open
conformation.33
Levosimendan interacts speciﬁcally with the hydropho-
bic region of cTnC close to its D/E linker domain on the
N-terminal region,35 where the consequence of levosimendan
binding is the stabilization of the open conformation of cTnC–
Ca2+ complex strengthening its binding to cTnI. In other words,
levosimendan increases the afﬁnity of cTnC–Ca2+ complex for
the cTnI and thus promoting a Ca2+ sensitizer effect through
a disinhibition mechanism.36 Levosimendan binds to cTnC in a
stereo-selective manner because it was reported to be a more
effective Ca2+ sensitizer agent than of its dextrorotatory stereo-
isomer referred as dextrosimendan.37 Ca2+ sensitization with
levosimendan offers increased cardiac contractility without
changes in the intracellular Ca2+ concentration.38
Ca2+ sensitizer agents may impair myocardial relaxation
due to Ca2+ sensitization at diastolic Ca2+ concentrations.39
Nevertheless, diastolic function is not impaired by
levosimendan treatment because drug binding to the N-terminal
region of cTnC is highly Ca2+ dependent with a subsequent
release from the binding site at diastolic Ca2+ levels.40 Addi-
tionally, the magnitude of Ca2+ sensitization with levosimen-
dan seems to be less than those of other Ca2+ sensitizing
agents, which is also favorable for myocardial relaxation.32
Moreover, positive lusitropic effects were also reported on
levosimendan administrations, and not only for the healthy
but also for the failing myocardium, as well.41
Phosphodiesterase Inhibitory Effect
of Levosimendan
Levosimendan was reported to be highly selective
enzyme inhibitors for the PDE III isoform in vitro.42 Never-
theless, its effects on cAMP-dependent intracellular protein
phosphorylation have not been supported equivocally.43,44
Preclinical data suggested that that levosimendan can exert
a positive inotropic effect through a Ca2+ sensitizing mecha-
nism without modiﬁcations in the intracellular cAMP concen-
trations.42 Of note, inhibition of the PDE III isoenzyme can be
compensated by PDE IV, and hence PDE III inhibition alone
might not be sufﬁcient to increase intracellular cAMP con-
centrations. Accordingly, different isoenzymes of the PDE
family (eg, PDE III and IV) are necessary to be blocked
simultaneously and for that, higher than therapeutic levosi-
mendan plasma concentrations should be used. The bottom
line is that nonselective PDE-inhibitors (eg, milrinone) are
expected to evoke more robust elevations in intracellular
cAMP levels than selective PDE-inhibitors.45
Vasodilating Effect of Levosimendan
Levosimendan possess vasodilator effects, which were
previously demonstrated at both of the arterial46 and venous47
sides of the vasculature as well as in coronary48 and pulmonary
arteries.49 The vasodilator property of levosimendan involves
the activation of various types of K+ channels with a conse-
quent hyperpolarization of the vascular smooth muscle cells.
This mechanism of action results in a decrease of the intracel-
lular Ca2+ concentration, initiating vascular relaxation.50
The opening of the glibenclamide-sensitive KATP chan-
nels was ﬁrst described as an important mediator of
levosimendan-induced vasodilatation by using patch clamp
technique in rat mesenteric arterial myocytes.51 Additionally,
voltage-gated (Kv) and Ca2+-activated K+ channels (BKCa)
were demonstrated to be involved in the levosimendan-
evoked vasorelaxation, as well.49 The proportion of the dif-
ferent K+ channels in the vasodilator responses may rely on
the size of the vessel, as it seems that levosimendan may
preferentially stimulate KV and BKCa channels in large con-
ductance vessels and the KATP channel in small resistance
vessels.52,53 Moreover, the origin of the vascular beds also
determines the vasodilator properties of levosimendan
because the vasodilator potential of levosimendan was not
identical in the pulmonary and peripheral vasculature.54
Organoprotective Effects of Levosimendan
More and more preclinical studies illustrate levosimen-
dan as a potent organoprotective drug, exerting its beneﬁcial
effects not only in the myocardial tissue,55 but also in the
FIGURE 2. Triple mechanism of action of levosimendan. Lev-
osimendan activates ATP-sensitive K+ (KATP) channels in vas-
cular smooth muscle cells. The consequent hyperpolarization
inhibits inward Ca2+ currents resulting in vasorelaxation.
Additionally, levosimendan exerts a Ca2+ sensitizing effect in
cardiomyocytes due to the interaction with cardiac troponin
C. Activating of the mitochondrial KATP in the cardiomyocytes
results in short- or long-term cardioprotection. KATP channel,
ATP-sensitive K+ channel; NCX, sodium-potassium exchanger;
ICaL, inward calcium current; SR Ca2+ ATPase, Sarcoplasmic
reticulum calcium ATPase.
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kidney,56 brain,57 liver,58 and in the gastrointestinal tract,59 as
well. Moreover, levosimendan was also reported to prevent
sepsis-induced multiorgan damage through its antiprolifera-
tive and antiinﬂammatory actions.60 Administration of levo-
simendan results in the downregulation of the NF-kB
dependent inﬂammatory pathway and in the decrease of the
excessive nitric oxide (NO) production in an experimental
model of septic shock.61 Leukocyte adhesion, inﬂammatory
cytokine production, and release of reactive O2 species were
also attenuated by levosimendan treatment protecting thereby
the failing heart and peripheral organs in septic shock.62,63
Cardioprotective properties of levosimendan may be
related directly to its beneﬁcial hemodynamic effects through
dilating the arterial and venous side of the vascular beds.
Consequent decrease in the preload and afterload may contrib-
ute to an energetically favorable condition related to the
reduction of myocardial O2 demand.64 In addition to its advan-
tageous vascular effects, myocardial protection evoked by lev-
osimendan administration is also implied as a consequence of
opening mitochondrial KATP (mKATP) channels.65 Accordingly,
activation of the mKATP channels initiates K+ inﬂux into the
mitochondria with a consecutive decrease of the mitochondrial
transmembrane potential, which stabilizes that organelle and
optimizes the energy production through improving the efﬁ-
ciency of the oxidative metabolism.65 Inhibitors of mKATP
channels (eg, 5-hydroxy-decanoic acid) can fully abolish the
antiischemic effect of levosimendan, suggesting a critical role
of mKATP channels in cardioprotection.66,67 Additionally,
changes in the membrane potential of the mitochondria inhibit
the opening of mitochondrial permeability transition pore,
which initiates an antiapoptotic pathway through aborting the
release of cytochrome c and activation of caspases.68
The cardioprotective action of levosimendan also involves
the activation of the reperfusion injury salvage kinase pathway
because its protein kinase B (Akt) and extracellular signal reg-
ulated kinase (Erk)-mediated central processes are upregulated
either directly or indirectly on levosimendan treatment.69,70 The
above cascades initiate antiproliferative, antiphagocyte, and anti-
apoptotic effects through phosphorylation-dependent processes
contributing to the levosimendan-induced preconditioning and
postconditioning.71
Furthermore, the cardioprotective effect of levosimendan
has been associated with NO-mediated pathways, and accord-
ingly enhanced NO production was reported in coronary
endothelial cells and in cardiomyocytes on levosimendan
administrations.72,73 It is currently debated, whether increased
NO production is mediated directly through reperfusion injury
salvage kinase–dependent signaling pathway or involves initial
mitochondrial processes by opening of mKATP channels. Any-
how, upregulated NO production elicits reduced cell death
during ischemia-reperfusion injury because of activating a col-
lection of diverse survival mechanisms.73–75
Taken together, the combination of the detailed
levosimendan-induced processes may be manifested clini-
cally as short- and long-term myocardial protection.76
Clinical Implication for Levosimendan Treatment
Levosimendan is generally well tolerated in patients
with AHF syndrome. Common side effects are hypotension
and headache due to its vasodilating properties occurring
more frequently in case of application with high loading
doses. Atrial ﬁbrillation, hypokalemia, and tachycardia are
considered as less common side effects.32
To answer the question of whether the use of levosi-
mendan might have overall favorable effects during acute and/
or decompensated HF, numerous clinical investigations have
been performed. The initial optimism driven by the improve-
ment of short- and mid-tem mortality in early clinical trials
(LIDO and RUSSLAN) was tempered by the less favorable
outcomes of recent studies (SURVIVE and REVIVE).77 Nev-
ertheless, more recent meta-analyses have reported that admin-
istration of levosimendan is associated with a signiﬁcant
reduction of mortality in critically ill patients and in those of
undergoing cardiac surgery.78,79 Possible explanation of this
discrepancy may emerge from the heterogeneity in clinical
characteristics of the patient populations included in previous
clinical studies. Additionally, concomitant vasodilator or
diuretic therapy and differences in dosage regimen may serve
with the most probable explanation for the partly disappointing
results in the SURVIVE and REVIVE studies.
Pimobendan
Pimobendan is a Ca2+ sensitizer agent with an added
PDE III inhibitory effect. The Ca2+ sensitizing and PDE III
inhibitor activity of pimobendan are exerted at the same con-
centration range.11 Ca2+ sensitization through binding to cTnC
is decreased in the failing human myocardium when compared
with that of nonfailing controls and can be abolished under
acidic conditions.80,81 Ca2+ overload due to PDE III inhibition
might be a potential source for the observed increased incidence
of arrhythmias. Accordingly, pimobendan was reported to
decrease the refractoriness of left ventricular (LV) enhancing
its susceptibility toward the development of ventricular arrhyth-
mias in a postinfarction dog model.82 Furthermore, chronic
pimobendan administration might trigger mitral valve regurgi-
tation and myocardial hypertrophy in dogs.83 Nevertheless,
pimobendan improved exercise capacity, LV performance,
and quality of life in patients with severe congestive heart
failure, although the risk for death was slightly increased.84
There is lacking clinical data, whether pimobendan treatment
would be beneﬁcial in patients with AHF syndrome.
TARGETING THE CARDIAC SARCOMERE WITH
MYOSIN ACTIVATORS
Targeting the cardiac sarcomere may be achieved by
using the so-called cardiac myosin activator agents, as well.
The theory behind this direct myosin activation is that selective
modulation of the kinetics of cardiac myosin heads would
improve cardiac performance while avoiding the adverse effects
of traditional inotropic drugs.85 It is to be mentioned that
myosin activation can be also regarded as a Ca2+-sensitizing
positive inotropic mechanism that targets the contractile process
downstream from the Ca2+–cTnC interaction.11
Omecamtiv Mecarbil
The goal of optimization during the development of
myoﬁlament targeted myosin activator agents was to ﬁnd
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a stable molecule for short intravenous or oral administration
while possessing favorable properties (eg, selectivity for
cardiac myosin or no effect on Ca2+ handling). Ultimately,
the drug candidate CK-1827452 was identiﬁed.86
Mechanism of Action of Omecamtiv Mecarbil
Omecamtiv mecarbil, previously referred as CK-
1827452, exerts a positive inotropy through its selective
binding to the S1 domain of the cardiac myosin where the
relay helix and converter domain converge at the base of the
force-producing lever arm. The mechanism of action evokes
a conformational change in the nucleotide-binding domain of
the cardiac myosin head contributing to the allosteric activa-
tion of its mechanical and enzymatic properties (Fig. 3).86
Importantly, myosin activation does not occur when fast
skeletal and smooth muscle myosin is present instead of the
cardiac isoform implying a cardioselective manner of the
omecamtiv mecarbil binding.87,88
Consistent with the allosteric modulation in the
nucleotide-binding domain of the cardiac myosin, omecamtiv
mecarbil, accelerates the inorganic phosphate release from the
myosin heads, which is the rate-limiting step of the acto-
myosin cycle. In other words, omecamtiv mecarbil increases
the ATPase rate of the cardiac myosin, accelerating thereby
the transition rate from the weakly to the strongly actin-bound
conformation. This kind of mechanism of action also suggests
that myosin activation may result in an increase of the
available force-producing myosin heads in the sarcomere,
indicating “more hands pulling on the rope.”87,88 Because
application of omecamtiv mecarbil is associated with
a decrease in the actin-independent release of Pi without
any changes in the Ca2+ homeostasis, the myocardial O2 con-
sumption remains unaltered parallel with its improved efﬁ-
ciency88 (Box 2).
Preclinical Trials
The putative positive inotropic effect of omecamtiv
mecarbil was ﬁrstly demonstrated by in vitro investigations.
Omecamtiv mecarbil signiﬁcantly increased the fractional
shortening in isolated rat cardiomyocytes without any
changes in the Ca2+ homeostasis measured by the ﬂuorescent
Ca2+ indicator. Furthermore, myosin activation resulted in an
increase not only in the magnitude but also in the duration of
contraction.87
In an in vivo dog model with pacing-induced systolic
HF after myocardial infarction or chronic pressure overload,
omecamtiv mecarbil infusion was shown to enhance LV
stroke volume, CO, and systolic ejection time in addition to
a decrease of HR, total peripheral vascular resistance, and
loading pressures. Additionally, myocardial O2 consumption
and the rate of LV pressure development (dP/dT) were not
affected by the application of omecamtiv mecarbil when com-
pared with that of traditional inotropes. Interestingly, ome-
camtiv mecarbil produced greater and more signiﬁcant
increases in the systolic properties of dogs with HF compared
with those of control healthy animals.89
One should also consider that increase in the systolic
ejection time must occur at the expense of diastole, impeding
thereby the ventricular and coronary ﬁlling. However, because
intravenous administration of omecamtiv mecarbil was reported
to decrease HR, improvements of systolic emptying should not
compromise diastolic function and coronary ﬂow.90
Clinical Consideration of Omecamtiv Mecarbil
Because the preclinical data demonstrated beneﬁcial
cardiovascular effects of myosin activation,91 omecamtiv me-
carbil was tested in a phase I study to determine the dose-
dependent augmentation of the cardiac function and the
maximum-tolerated doses and plasma concentration of the
drug.92 In the ﬁrst-in-men dose-escalating study, omecamtiv
mecarbil was reported to enhance the systolic functions of the
LV in a dose- and concentration-dependent manner using
a dose range of 0.005–1 mg21$kg$h21. Cardiac myosin acti-
vation was not accompanied by impairments in the diastolic
functions in those of healthy volunteers. Additionally, the
maximum-tolerated dose for omecamtiv mecarbil was
0.5 mg21$kg$h21 without any dose-related adverse effects.
FIGURE 3. Actin–myosin cycling involves coupled bio-
chemical and mechanical events. ATP binding to the myosin
heads results in a dissociation from the actin filaments. Then,
ATP is hydrolyzed to ADP + Pi. In the presence of Ca2+, the
myosin head binds to the actin filament forming a weakly
attached conformation. Thereafter, Pi dissociates from the
myosin heads resulting in a high affinity cross-bridge accom-
panied by the force producing power stroke step. Omecamtiv
mecarbil interferes with the rate-limiting step of the actin–
myosin cycle by accelerating Pi release from the myosin heads.
Consequently, omecamtiv mecarbil increases the number of
force-generating myosin heads contributing to enhanced
cardiac contractility.
Mechanism of Action of Omecamtiv Mecarbil
! Myosin activation through cardioselective binding to
myosin heads
! Acceleration of the rate-limiting Pi release step of the
actin–myosin cycle
! More hands pulling on the rope
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The dose-limiting toxic effect was myocardial ischemia due
to the detailed prolongation of the systolic ejection time.92
Subsequently, a double-blind, placebo-controlled, dose-
ranging phase II trial was carried out in patients with systolic
HF to elucidate the safety and tolerability of omecamtiv
mecarbil. This clinical investigation revealed that the cardio-
vascular effects of the myosin activator were comparable with
those of healthy volunteers assessed in the phase I study. The
well-tolerated plasma concentration of omecamtiv mecarbil
was proved to be within a range of 100–1200 ng/mL. At
a higher plasma concentration, some of the patients revealed
signs of myocardial ischemia due to the excessive prolonga-
tion of the systolic ejection time.93
Most recently, a randomized, controlled phase IIb trial
(ATOMIC-AHF) was undertaken to evaluate the safety and
efﬁciency of omecamtiv mecarbil in those of hospitalized
with AHF. The ATOMIC-AHF revealed that myosin activa-
tion did not meet the primary end point of the study because
no signiﬁcant effect on dyspnea was demonstrated. Neverthe-
less, administration of omecamtiv mecarbil proved to be
clinically safe, and the results also suggested a tendency
towards reduction of worsening HF.94–96
Taken together, omecamtiv mecarbil seems to be a very
promising approach for the treatment of systolic HF, although
further clinical investigations should be evolved to elucidate
whether the theory of myosin activation may be translated
into the clinical practice.
CARDIOVASCULAR DRUGS WITH ADDED
MYOFILAMENTAL EFFECTS—A
FUTURE PERSPECTIVE
In addition to the Ca2+ sensitization with levosimendan
and myosin activation with omecamtiv mecarbil, other car-
diovascular drugs were reported to possess with added my-
oﬁlamental effects. For example, SR-33805 and CXL-1020
can be also considered as an inotropic agent targeting the
cardiac sarcomere.22,97 Although the beneﬁcial cardiovascular
effects of the drugs with added myoﬁlamental effects were
demonstrated previously in preclinical investigations, further
clinical trials should be performed to determine whether those
applications would serve with a future perspective in the
therapy of AHF syndrome.
SR-33805 was characterized ﬁrstly as a potent L-type
Ca2+ channel (LTP) inhibitor with a consequent negative
inotropic effect in electrically stimulated healthy rabbit prep-
arations.98 Interestingly, SR-33805 did not affect the Ca2+
transient in failing cardiomyocytes suggesting that its effect
depends mainly on the membrane potential itself. Because HF
is characterized by abnormalities in the excitation–contraction
coupling and Ca2+ handling, electric remodeling with depo-
larized membrane potential may explain the decreased capac-
ity of SR-33805 to inhibit LTP in failing myocytes.99
Moreover, SR-33805 was demonstrated as a potent positive
inotropic agent improving the contractility of the failing rat
hearts by a Ca2+-sensitizing mechanism relying on 2 different
strategies.100 Direct sensitization of the myoﬁlaments was
demonstrated by force measurements in permeabilized
myocyte-sized preparations after in vitro SR-33805
treatment.101 Additionally, SR-33805 targets in vivo the phos-
phorylation status of Ser23/24 in cTnI by an inhibition of
protein kinase A activity, resulting thereby in enhanced
responsiveness of the cardiac myoﬁlaments for Ca2+. Another
interesting feature of SR-33805 is its beneﬁcial effect on
myocardial relaxation.100
HNO donor agents were previously shown to have
beneﬁcial cardiovascular effects. Accordingly, HNO donated
by Angeli’s salt exerted a positive inotropic and lusitropic
action in dogs with HF induced by chronic LV pacing inde-
pendently from the b-adrenergic signaling.102 However, the
clinical utility of Angeli’s salt remained limited due to its chem-
ical instability. A chemically unrelated agent, CXL-1020, was
demonstrated to reduce both of LV and RV ﬁlling pressures
and SVR similarly to that of Angeli’s salt, while increasing CO
and stroke volume index in patients with systolic HF.103 HNO
is hypothesized to interact with speciﬁc reactive thiol groups
present in the contractile machinery promoting thereby the
maximal Ca2+ activated force production.104 Accordingly,
HNO-mediated disulﬁde bond formation between critical cys-
teine residues of cardiac myoﬁlaments enhanced contractile
function by increasing myoﬁlamental responsiveness to Ca2+.
Those ﬁndings indicate thereby a redox-based posttranslational
modiﬁcation in the cardiac sarcomere, providing a potential
therapeutic approach for HF.105 In addition to that of direct
myoﬁlamental effects, CXL-1020 is capable of increasing LV
contractility by enhancing the Ca2+ cycling of the SR, as well.22
Hence, HNO enhances ryanodin receptor 2 and SERCA2a
activity without recruiting extracellular Ca2+ through L-type
Ca2+ channels.22,106,107
CONCLUSIONS
Little progress has been made in the therapy of AHF
syndrome during the last decades. Previous guidelines
emphasized, that clinical application of Ca2+ mobilizer ino-
tropes may have beneﬁcial effects by increasing the cardiac
contractility at whatever cost. Nevertheless, this hypothesis
failed because recent clinical trials proved that impaired clin-
ical outcome does not necessary follow the increased cardiac
performance. Limitations of traditional inotropic therapy may
be attributed to their mechanisms of action. Ca2+ mobilization
increasing Ca2+ load may worsen ischemia by enhancing
myocardial O2 consumption and increasing the risks for ar-
rhythmias. Sarcomere targeted agents can potentially alleviate
these problems. Novel strategies with Ca2+ sensitizers with or
without additional effects exhibit promising preclinical and
clinical results. Nevertheless, further clinical trials will help
to decide, whether this hypothesis can be translated into
favorable clinical outcome. However, because levosimendan
has shown evidence of short-term beneﬁts without adverse
long-term events, we think this should be the minimum stan-
dard for any future inotropic or inodilator drug developed for
the treatment of HF.
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